AUA: Pandemic Disruptions Impacted One in Four Prostate, Bladder Cancer Patients
Changes, delays, and cancellation of cancer treatment and ancillary care reported.
Changes, delays, and cancellation of cancer treatment and ancillary care reported.
Of more than 100 studies used to support drug approvals, none reported information on the gender of participants.
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
The use of proton beam therapy (PBT) increased between 2004 and 2018, particularly for cancers in which the effectiveness of PBT is still under investigation.
Orteronel is likely not effective when compared with recently approved agents, according to researchers.
Disparities greatest most recently and for cancers for which PBT is the recommended radiation therapy modality.
Researchers sought to understand how men with prostate cancer interpret the signs and symptoms of their disease and treatment in relation to their prognosis.
However, there were no statistically significant changes in rates by race.
Study confirms the care gap in bone health management and fracture prevention among older men with prostate cancer receiving androgen deprivation therapy.
Camcevi is a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, a gonadotropin-releasing hormone agonist.